AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Granier, S. A.
Right arrow Articles by Nicolas-Chanoine, M.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granier, S. A.
Right arrow Articles by Nicolas-Chanoine, M.-H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2002, p. 1158-1159, Vol. 46, No. 4
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.4.1158-1159.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

First Description of a TEM-30 (IRT-2)-Producing Klebsiella oxytoca Isolate


   LETTER
Top
 Letter
References
 
Both Klebsiella oxytoca and Klebsiella pneumoniae synthesize a chromosomal class A ß-lactamase (KOXY and LEN-1, respectively), but K. oxytoca harbors acquired plasmid-mediated ß-lactamases much less often (10%) than K. pneumoniae (90%) (8). Increased and extended resistance to ß-lactams in K. oxytoca (10 to 20% of the clinical isolates) is generally imputed to the overproduction of KOXY ß-lactamase due to point mutations in the promoter region (3, 8).

However, some K. oxytoca isolates producing plasmid-mediated extended-spectrum ß-lactamases have been described (5) and, more recently, two isolates which displayed a ß-lactamase inhibitor-resistant (IR) phenotype were described (1, 9). The first isolate produced an OXY-2 ß-lactamase with the amino acid substitution Ser130Gly responsible for the IR phenotype (9). The second isolate harbored a plasmid-mediated TEM-2 derivative (TEM-59, IRT-17) which also showed the amino acid substitution Ser130Gly (1). We report here on a K. oxytoca isolate (SG 81) which also displayed an IR phenotype on the basis of the disk diffusion method: highly resistant to amoxicillin, even in the presence of clavulanate; relatively resistant to ticarcillin; and fully susceptible to cephalosporins.

As no associated resistance was observed, the KOXY-encoding gene was studied first, with gene amplification and sequencing using the primers OXY-A (5'-TCGGTAACTGTGACGGGA-3') and OXY-B (5'-CCGAATTTCGGGAAGCCA-3'). This gene was affiliated to blaOXY-2 and differed from the blaOXY-2 gene of K. oxytoca strain SL911 by two mutations, one of them leading to the amino acid substitution Val260Ile (4). As this substitution had never been involved in any IR phenotype, the plasmidic content of this strain was then studied.

Conjugation between K. oxytoca SG 81 and Escherichia coli K-12 C600S1000 (lac negative; streptomycinr) and thereafter between E. coli transconjugants and K. oxytoca reference strain SL911 (OXY-2 ß-lactamase) were carried out by a broth mating procedure. E. coli transconjugants were selected at a frequency of 4 x 10-6. MIC determinations for donors, recipients, and transconjugants were performed by the agar dilution method using fixed concentrations of ß-lactamase inhibitors and variable concentrations of antibiotics, and vice versa. The two types of transconjugants displayed the same IR phenotype as K. oxytoca SG 81, suggesting that the genetic support of the IR phenotype was a conjugative plasmid (Table 1).


View this table:
[in this window]
[in a new window]
  		TABLE 1. MICs of ß-lactam antibiotics and ß-lactamase inhibitors against K. oxytoca strain SG 81, recipient strains, and transconjugants

 
This plasmid was extracted and its size was estimated to be 40 kb. In order to further characterize this plasmid which displayed no other markers of antibiotic resistance, mercury resistance was tested as recommended by Liebert et al. (7), but the isolate was found susceptible to this compound. The incompatibility group of this plasmid was also studied as previously described (2), and we found that our plasmid was compatible with the T, 6-C, 7-M, FII, N, I1, X, M, 10-B-O, I2, FIV, J, and W groups.

As IR phenotype is essentially due to TEM-type enzymes, a blaTEM-specific PCR was performed on a crude extract of DNA from K. oxytoca SG 81 as previously described (10). The sequence analysis of the amplified product showed that the blaTEM gene displayed two mutations in comparison toblaTEM-1A, namely, the silent mutation T -> C at position 436 and the mutation A -> C at position 929, leading to the amino acid substitution Arg244Ser according to Ambler numbering. It was thus demonstrated that the blaTEM gene derived from blaTEM-1C had a weak promoter P3 and encoded the TEM-30 (IRT-2) ß-lactamase. The previously published TEM-30 in E. coli isolates, derived from blaTEM-1A, -1B, -1D, and -1F but not from blaTEM-1C, had, in the majority of cases, a strong promoter, Pa/Pb or P4 (6).

To our knowledge, this is the first description of TEM-30 in K. oxytoca.


   ACKNOWLEDGMENTS
 
We thank B. Fournier for providing reference strain SL911.


   REFERENCES
Top
 Letter
 References
 

  1. Bermudes, H., F. Jude, E. B. Chaibi, C. Arpin, C. Bebear, R. Labia, and C. Quentin. 1999. Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived beta-lactamase in a clinical isolate of Klebsiella oxytoca. Antimicrob. Agents Chemother. 43:1657-1661.[Abstract/Free Full Text]
  2. Chabbert, Y. A., M. R. Scavizzi, J. L. Witchitz, G. R. Gerbaud, and D. H. Bouanchaud. 1972. Incompatibility groups and the classification of fi- resistance factors. J. Bacteriol. 112:666-675.[Abstract/Free Full Text]
  3. Fournier, B., C. Y. Lu, P. H. Lagrange, R. Krishnamoorthy, and A. Philippon. 1995. Point mutation in the Pribnow box, the molecular basis of beta-lactamase overproduction in Klebsiella oxytoca. Antimicrob. Agents Chemother. 36:1365-1368.
  4. Fournier, B., P. H. Roy, P. H. Lagrange, and A. Philippon. 1996. Chromosomal beta-lactamase genes of Klebsiella oxytoca are divided into two main groups, blaOXY-1 and blaOXY-2. Antimicrob. Agents Chemother. 40:454-459.[Abstract]
  5. Hadziyannis, E., M. Tuohy, L. Thomas, G. W. Procop, J. A. Washington, and G. S. Hall. 2000. Screening and confirmatory testing for extended spectrum beta-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca clinical isolates. Diagn. Microbiol. Infect. Dis. 36:113-117.[CrossRef][Medline]
  6. Leflon-Guibout, V., B. Heym, and M. H. Nicolas-Chanoine. 2000. Updated sequence information and proposed nomenclature for blaTEM genes and their promoters. Antimicrob. Agents Chemother. 44:3232-3234.[Abstract/Free Full Text]
  7. Liebert, C. A., J. Wireman, T. Smith, and A. O. Summers. 1997. Phylogeny of mercury resistance (mer) operons of gram-negative bacteria isolated from the fecal flora of primates. Appl. Environ. Microbiol. 63:1066-1076.[Abstract]
  8. Reig, R., C. Roy, M. Hermida, D. Teruel, and A. Coira. 1993. A survey of beta-lactamases from 618 isolates of Klebsiella spp. J. Antimicrob. Chemother. 31:29-35.[Abstract/Free Full Text]
  9. Sirot, D., R. Labia, P. Pouedras, C. Chanal-Claris, C. Cerceau, and J. Sirot. 1998. Inhibitor-resistant OXY-2 derived beta-lactamase produced by Klebsiella oxytoca. Antimicrob. Agents Chemother. 42:2184-2187.[Abstract/Free Full Text]
  10. Speldooren, V., B. Heym, R. Labia, and M. H. Nicolas-Chanoine. 1998. Dis-criminatory detection of inhibitor-resistant beta-lactamases in Escherichia coli by single-strand conformation polymorphism-PCR. Antimicrob. Agents Chemother. 42:879-884.[Abstract/Free Full Text]
Sophie A. Granier
Jean-Claude Nguyen Van
Marie-Dominique Kitzis
Fred W. Goldstein
Véronique Leflon-Guibout
Marie-Hélène Nicolas-Chanoine*
Laboratoire de Microbiologie Médicale
Fondation Hôpital Saint-Joseph
Service de Microbiologie-Hygiène
Hôpital A. Paré
9 avenue Charles de Gaulle
92100 Boulogne-Billancourt, France

* Corresponding author. Mailing address: Service de Microbiologie-Hygiène, Hôpital A. Paré, 9 avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France. Phone: 33-1-49-09-55-40. Fax: 33-1-49-09-59-21. E-mail: marie-helene.nicolas-chanoine{at}apr.ap-hop-paris.fr.

Antimicrobial Agents and Chemotherapy, April 2002, p. 1158-1159, Vol. 46, No. 4
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.4.1158-1159.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Granier, S. A.
Right arrow Articles by Nicolas-Chanoine, M.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granier, S. A.
Right arrow Articles by Nicolas-Chanoine, M.-H.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS